Fund BasicsSee More
- Fund Family BlackRock iShares
- Assets Under Management 305,424,000
- Shares Outstanding, K 6,300
- 60-Month Beta 0.82
- Price/Earnings ttm 28.20
- Annual Dividend & Yield 0.12
- Most Recent Dividend 0.036
- Management Fee 0.47%
|Period||Period Low||Period High||Performance|
| || |
-5.88 (-11.13%)since 02/02/21
| || |
+2.01 (+4.47%)since 12/02/20
| || |
+16.46 (+53.96%)since 03/02/20
The coronavirus pandemic triggered a race to introduce vaccine and treatment, thereby opening up new investing opportunities in the biotech sector in 2020.
Positive coronavirus vaccine progress from Moderna (MRNA) has hogged investors' attention.
Bayer has made a big bet on gene therapy by announcing the acquisition of U.S. biotech firm Asklepios BioPharmaceutical for as much as $4 billion.
Positive comment on coronavirus vaccine progress from Moderna's (MRNA) CEO during The Wall Street Journal's annual Tech Live conference has gained investors attention and raised vaccine optimism.
Genomics ETFs have surged of late; here's why
The announcement of the 2020 Nobel Prize winners for Chemistry has successfully brought investor attention to the gene-editing space.
The healthcare sector defied last week's market rout buoyed by the progress in the development of a coronavirus vaccine or treatment, and merger and acquisition news.
Per the latest data from an early stage clinical trial, Moderna's experimental coronavirus vaccine is successfully producing neutralizing antibodies and T-cells in older adults.
Small-cap biotech ETFs may prove to be winning bets with or without coronavirus.
Moderna has inked a $1.5-billion coronavirus vaccine supply agreement with the U.S. government.
|3rd Resistance Point||48.72|
|2nd Resistance Point||48.36|
|1st Resistance Point||47.66|
|1st Support Level||46.61|
|2nd Support Level||46.25|
|3rd Support Level||45.56|